Trading Signals: UTHR Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)( United Therapeutics Corp)
| UTHR latest price $114.3900 (-2.2%) ($113.8600 - $117.1400) on Fri. Nov. 9, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.19% (three month average) | RSI | 42 | Latest Price | $114.3900(-2.2%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | UTHR declines -1.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support UTHR advance at 0% a week (0% probability) XLV(44%) IBB(43%) XBI(42%) VFMO(40%) VT(40%) | Factors Impacting UTHR price | UTHR will decline at least -1.095% in a week (0% probabilities). VXX(-14%) TLT(-14%) VIXM(-12%) UUP(-10%) DIA(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.095% (StdDev 2.19%) | Hourly BBV | 0 () | Intraday Trend | -1.8% | | | |
|
1 - 5 Day Possible Target | $110.22(-3.65%) | Resistance Level | $119.13 | 5 Day Moving Average | $115.99(-1.38%) | 10 Day Moving Average | $116.04(-1.42%) | 20 Day Moving Average | $119.13(-3.98%) | To recent high | -11.6% | To recent low | 3.2% | Market Cap | $5.074b | | | | United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD. |